High levels of CB2 expression in either gliomas or endothelial cells of glioblastoma vessels are also demonstrated by Schley et al. [15], which suggests that these tumors can be vulnerable to a cannabinoid treatment thereby hinting at a CB2 cannabinoid specific agonist-based strategy. Here, CNR2 is linked to glioma.